Tomáš Štulc

1.3k total citations
58 papers, 1.0k citations indexed

About

Tomáš Štulc is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Tomáš Štulc has authored 58 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 17 papers in Cardiology and Cardiovascular Medicine and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Tomáš Štulc's work include Lipoproteins and Cardiovascular Health (26 papers), Cancer, Lipids, and Metabolism (11 papers) and Cardiovascular Health and Disease Prevention (8 papers). Tomáš Štulc is often cited by papers focused on Lipoproteins and Cardiovascular Health (26 papers), Cancer, Lipids, and Metabolism (11 papers) and Cardiovascular Health and Disease Prevention (8 papers). Tomáš Štulc collaborates with scholars based in Czechia, United States and Austria. Tomáš Štulc's co-authors include R Češka, Peter P. Tóth, Ricardo Dent, Maciej Banach, Michal Vráblík, Aleksi Šedo, Antonio M. Gotto, Jan Malík, J Škrha and Betsie Boucher and has published in prestigious journals such as Journal of Clinical Investigation, The American Journal of Cardiology and European Journal of Pharmacology.

In The Last Decade

Tomáš Štulc

54 papers receiving 957 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomáš Štulc Czechia 16 567 263 258 198 171 58 1.0k
B. Angelin Sweden 18 623 1.1× 290 1.1× 207 0.8× 134 0.7× 210 1.2× 36 1.1k
Eliana Polisecki United States 17 473 0.8× 229 0.9× 163 0.6× 128 0.6× 110 0.6× 32 829
Michael V. Holmes United Kingdom 16 361 0.6× 255 1.0× 234 0.9× 389 2.0× 59 0.3× 25 1.2k
Tiziana Sampietro Italy 18 594 1.0× 356 1.4× 195 0.8× 299 1.5× 49 0.3× 75 1.1k
Therèse Heinonen Canada 19 691 1.2× 221 0.8× 242 0.9× 334 1.7× 58 0.3× 39 1.2k
Mark A. Milad United States 15 333 0.6× 187 0.7× 126 0.5× 80 0.4× 175 1.0× 24 966
Isabelle L. Ruel Canada 21 1.0k 1.8× 597 2.3× 320 1.2× 328 1.7× 135 0.8× 69 1.5k
Margaret R. Diffenderfer United States 21 923 1.6× 700 2.7× 257 1.0× 272 1.4× 121 0.7× 50 1.4k
Melchior C. Nierman Netherlands 15 357 0.6× 325 1.2× 218 0.8× 542 2.7× 53 0.3× 32 1.1k
Yu Lin United States 20 320 0.6× 177 0.7× 477 1.8× 421 2.1× 102 0.6× 25 1.4k

Countries citing papers authored by Tomáš Štulc

Since Specialization
Citations

This map shows the geographic impact of Tomáš Štulc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Štulc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Štulc more than expected).

Fields of papers citing papers by Tomáš Štulc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Štulc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Štulc. The network helps show where Tomáš Štulc may publish in the future.

Co-authorship network of co-authors of Tomáš Štulc

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Štulc. A scholar is included among the top collaborators of Tomáš Štulc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Štulc. Tomáš Štulc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vráblík, Michal, Jan Piťha, V. Bláha, et al.. (2019). Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Vnitřní lékařství. 65(12). 743–754.
2.
3.
Češka, R, et al.. (2017). [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].. PubMed. 62(11). 887–894. 2 indexed citations
4.
Štulc, Tomáš, et al.. (2017). A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. Archives of Medical Science. 4(4). 705–710. 8 indexed citations
5.
Soška, Vladimír, Michal Vráblík, V. Bláha, et al.. (2016). [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].. PubMed. 62(4). 329–33. 1 indexed citations
6.
Banach, Maciej, Tomáš Štulc, Ricardo Dent, & Peter P. Tóth. (2016). Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology. 225. 184–196. 146 indexed citations
7.
Štulc, Tomáš, R Češka, & Antonio M. Gotto. (2016). Statin intolerance: the clinician’s perspective. 12 indexed citations
8.
Češka, R & Tomáš Štulc. (2014). Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?. Current Pharmaceutical Design. 21(9). 1180–1184. 1 indexed citations
9.
Soška, Vladimír, H Vaverková, Michal Vráblík, et al.. (2013). Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. Interní medicína pro praxi. 15(10). 322–326.
10.
Svobodová, Helena, et al.. (2009). The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus. Physiological Research. 58(5). 701–707. 4 indexed citations
11.
Hubáček, Jaroslav A., Zdena Škodová, Věra Adámková, et al.. (2008). APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clinical Chemistry and Laboratory Medicine (CCLM). 46(6). 773–7. 11 indexed citations
12.
Štulc, Tomáš, et al.. (2008). Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment. Physiological Research. 57(2). 185–194. 17 indexed citations
13.
Svobodová, Helena, et al.. (2007). Apolipoprotein E Gene Polymorphism in the Mongolian Population. Folia Biologica. 53(4). 138–142. 28 indexed citations
14.
Petrák, Ondřej, J Widimský, Tomáš Zelinka, et al.. (2006). Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. Physiological Research. 55(6). 597–602. 11 indexed citations
15.
Malík, Jan, Dan Wichterle, T Haas, et al.. (2004). Repeatability of noninvasive surrogates of endothelial function. The American Journal of Cardiology. 94(5). 693–696. 27 indexed citations
16.
Štulc, Tomáš, et al.. (2003). Microvascular reactivity in patients with hypercholesterolemia: the effect of lipid lowering treatment. Physiological Research. 439–445. 23 indexed citations
17.
Vráblík, Michal, Aleš Hořínek, R Češka, Tomáš Štulc, & Tomáš Kvasnička. (2003). Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136→Cys) gene variant.. Physiological Research. 52(5). 647–650. 5 indexed citations
18.
Melenovský, Vojtěch, Tomáš Štulc, Viktor Kožich, et al.. (2003). Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. American Heart Journal. 146(1). 110A–115A. 20 indexed citations
19.
Štulc, Tomáš & R Češka. (2001). Cholesterol lowering and the vessel wall: new insights and future perspectives. Physiological Research. 50(5). 461–471. 10 indexed citations
20.
Redlich, Kurt, Peter Pietschmann, Tomáš Štulc, & Meinrad Peterlik. (1997). Comparative Study on the Effect of Calcium Channel Blockers on Basal and Parathyroid Hormone‐Induced Bone Resorptionin vitro. Pharmacology & Toxicology. 80(6). 262–265. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Angelin Breakdown of academic impact, for papers by Eliana Polisecki Breakdown of academic impact, for papers by Michael V. Holmes Breakdown of academic impact, for papers by Tiziana Sampietro Breakdown of academic impact, for papers by Therèse Heinonen Breakdown of academic impact, for papers by Mark A. Milad Breakdown of academic impact, for papers by Isabelle L. Ruel Breakdown of academic impact, for papers by Margaret R. Diffenderfer Breakdown of academic impact, for papers by Melchior C. Nierman Breakdown of academic impact, for papers by Yu Lin
Rankless by CCL
2026